Myricx plans to conduct preclinical as well as clinical development of the newly developed ADC for solid tumours. Credit: Gorodenkoff / Shutterstock.com.

UK-based biotech company Myricx Bio has signed a licence agreement for contract research, development and manufacturing organisation (CRDMO) WuXi Biologics’s antibody. 

WuXi discovered the antibody using its integrated technology platforms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Myricx plans to advance the antibody into an antibody-drug conjugate (ADC), leveraging its NMTi payload platform.

This platform has a well-differentiated profile compared to conventional payload classes, comprising microtubule and topoisomerase inhibitors. 

Myricx will conduct preclinical and clinical development of the ADC for solid tumours that are difficult to treat. 

WuXi Bio will receive an upfront payment from Myricx. 

Myricx will also make milestone payments on meeting development and commercialisation goals, apart from royalty payments on net product sales.

Myricx CEO Dr Robin Carr stated: “We believe that combining this leading antibody with our novel NMTi-based payload will create an ADC with significant clinical differentiation in solid tumours. 

“Based on our positive preclinical data, we believe NMTi-ADCs offer a highly differentiated mechanism of action, superb efficacy and good tolerability across different cancer targets.”

Myricx recently announced data demonstrating the potential of its NMTi payload platform across tumour-linked antigens including B7-H3, TROP2 and HER2.

The latest deal with WuXi is the second licence deal of its kind signed by Myricx.

In September 2023, Myricx and Biocytogen Pharmaceuticals entered an agreement for the development and commercialisation of ADCs based on an antibody designed using the latter’s RenMice platform.

WuXi Biologics CEO Dr Chris Chen stated: “This licence agreement with Myricx is another testament [to] our proprietary integrated platform and the R in our CRDMO business model. 

“We are looking forward to enabling global clients to develop more first-in-class and best-in-class biologics drugs for the benefit of patients worldwide.”